Bellicum Pharmaceuticals, Inc. - BLCM STOCK NEWS

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced promising early results from a Phase 1 trial of BPX-601 for metastatic castration-resistant prostate cancer (mCRPC). The trial showed a 50% PSA50 response rate among patients, with some achieving a PSA90 response. Patients received lymphodepleting chemotherapy followed by BPX-601 cells and rimiducid. Notably, adverse effects included grade 3+ events such as myelosuppression and cytokine release syndrome. The trial continues, with future cohorts aiming to explore higher doses of rimiducid to enhance efficacy. These initial results support the potential of the GoCAR-T platform.

Bellicum Pharmaceuticals (NASDAQ:BLCM) corrected a previous press release regarding stock options. The company granted 20,000 stock options, not the initially reported 45,000, to one new employee. This grant was approved by the Compensation Committee on January 31, 2023, and has an exercise price of $1.14 per share. The options vest over four years, with 25% vesting at the one-year mark and the remainder vesting monthly thereafter, contingent on the employee's continued service. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are issued under the 2019 Equity Incentive Plan.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced on January 31, 2023, that it has granted 45,000 stock options to a new employee. The grants were approved by the Compensation Committee of the Board of Directors, effective the same date. The stock options have an exercise price of $1.14 per share and will vest over four years. This aligns with Nasdaq Listing Rule 5635(c)(4) regarding inducements for new employees. Bellicum focuses on developing innovative cellular immunotherapies for cancer treatment, emphasizing their GoCAR-T® products, BPX-601 and BPX-603, designed to enhance CAR-T cell therapy efficacy.

Bellicum Pharmaceuticals (NASDAQ: BLCM) announced that an abstract detailing early results from a Phase 1 clinical trial of BPX-601, its lead GoCAR-T^® product, has been accepted for presentation at the 2023 ASCO Genitourinary Cancers Symposium. The trial focuses on patients with metastatic castration-resistant prostate cancer and will be showcased on February 16, 2023, in San Francisco. This presentation highlights Bellicum's innovative approach to CAR-T cell therapies, aiming for greater efficacy in cancer treatment through controllable cell signaling technologies.

Bellicum Pharmaceuticals (BLCM) announced a poster presentation at the 64th ASH Annual Meeting, highlighting findings from the University of North Carolina Lineberger Cancer Center. The study involved four patients treated with rimiducid to manage ICANS related to CD19-specific CAR-T therapy. The results indicated that rimiducid could significantly reduce severe ICANS symptoms within 24 hours. Bellicum's leadership expressed optimism about the technology's potential in improving patient outcomes and reducing toxicities associated with CAR-T therapies.

Bellicum Pharmaceuticals (BLCM) reported its Q3 2022 financial results, showing revenues of $1.0 million, significantly down from $5.0 million in Q3 2021. The company faced challenges due to a fludarabine shortage, affecting clinical trials BPX-601 and BPX-603. R&D expenses rose to $6.9 million due to increased personnel costs. The net loss was $7.2 million for the quarter, compared to a net income of $1.2 million in Q3 2021. Bellicum had $28.8 million in cash at the end of September 2022, down from $47.7 million at the end of 2021.

Bellicum Pharmaceuticals (NASDAQ:BLCM) announced the grant of 45,000 stock options to a new employee, effective October 31, 2022. These options, with an exercise price of $1.06 per share, vest over four years. 25% will vest on the one-year anniversary of the vesting commencement date, with monthly vesting for the remaining shares. This grant is in compliance with Nasdaq Listing Rule 5635(c)(4) and is part of the company's 2019 Equity Incentive Plan. Bellicum focuses on developing controllable cell therapies, particularly CAR-T cell therapies to enhance efficacy.

Bellicum Pharmaceuticals (Nasdaq: BLCM) is set to present at the 2022 Cell & Gene Meeting on the Mesa, occurring from October 11-13 in Carlsbad, CA. CEO Rick Fair will speak on October 11 at 4:30 p.m. PT. The event will showcase over 90 presentations highlighting advancements in cell and gene therapies, with the option for virtual attendance. Credentialed investors and media can attend for free, with registration details available online. Bellicum focuses on controllable cell therapies, aiming to enhance CAR-T cell efficacy through innovative product candidates like GoCAR-T®.

Bellicum Pharmaceuticals (BLCM) announced the grant of 70,000 stock options to a new employee, approved by its Compensation Committee, with an effective date of September 30, 2022. The options have an exercise price of $1.20 per share and will vest over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's commitment to attracting talent. Bellicum focuses on developing controllable cellular immunotherapies for cancer, enhancing CAR-T cell therapies through innovative technologies.